Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Rubius TherapeuticsInhibrxMesoblastAdverum BiotechnologiesTaysha Gene Therapies
SymbolNASDAQ:RUBYNASDAQ:INBXNASDAQ:MESONASDAQ:ADVMNASDAQ:TSHA
Price Information
Current Price$24.76$18.48$8.81$8.96$23.01
52 Week RangeHoldBuyHoldBuyBuy
MarketRank™
Overall Score1.81.61.41.51.8
Analysis Score2.13.53.23.43.5
Community Score2.32.93.12.44.0
Dividend Score0.00.00.00.00.0
Ownership Score4.20.80.01.70.8
Earnings & Valuation Score0.60.60.60.00.6
Analyst Ratings
Consensus RecommendationHoldBuyHoldBuyBuy
Consensus Price Target$28.00$34.67$14.55$23.50$43.92
% Upside from Price Target13.09% upside87.59% upside65.15% upside162.28% upside90.86% upside
Trade Information
Market Cap$2.01 billion$697.58 million$1.14 billion$876.25 million$868.88 million
Beta2.37N/A3.711.72N/A
Average Volume1,671,754145,834575,167835,38290,960
Sales & Book Value
Annual RevenueN/AN/A$32.16 million$250,000.00N/A
Price / SalesN/AN/A35.543,505.01N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$3.44 per shareN/A$4.70 per share$2.71 per shareN/A
Price / BookN/AN/A1.873.31N/A
Profitability
Net Income$-163,460,000.00N/A$-77,940,000.00$-64,490,000.00N/A
EPS($2.08)N/A($0.74)($1.01)N/A
Trailing P/E RatioN/A0.00N/AN/A0.00
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-591.00%N/AN/A
Return on Equity (ROE)-77.33%N/A-18.69%-32.23%N/A
Return on Assets (ROA)-49.05%N/A-13.85%-28.02%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.43%0.18%0.10%N/AN/A
Current Ratio7.15%3.80%1.32%28.53%24.02%
Quick Ratio7.15%3.80%1.32%28.53%24.02%
Ownership Information
Institutional Ownership Percentage93.74%36.63%2.80%97.41%42.19%
Insider Ownership Percentage58.40%N/A18.80%12.40%N/A
Miscellaneous
Employees2048410216738
Shares Outstanding81.23 million37.75 million129.74 million97.80 million37.76 million
Next Earnings Date5/10/2021 (Estimated)6/11/2021 (Estimated)5/26/2021 (Estimated)5/27/2021 (Estimated)6/2/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableOptionableNot Optionable
SourceHeadline
Morgan Stanley Increases Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $43.00Morgan Stanley Increases Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $43.00
americanbankingnews.com - April 19 at 1:10 PM
Chardan Capital Increases Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $67.50Chardan Capital Increases Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $67.50
americanbankingnews.com - April 19 at 12:35 PM
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $24.91Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $24.91
americanbankingnews.com - April 19 at 11:40 AM
 Brokerages Anticipate Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Will Post Earnings of -$0.54 Per Share Brokerages Anticipate Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Will Post Earnings of -$0.54 Per Share
americanbankingnews.com - April 17 at 12:50 PM
Taysha Gene Therapies (NASDAQ:TSHA) Sees Large Volume IncreaseTaysha Gene Therapies (NASDAQ:TSHA) Sees Large Volume Increase
americanbankingnews.com - April 15 at 11:40 AM
Oppenheimer Analysts Cut Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Oppenheimer Analysts Cut Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA)
americanbankingnews.com - April 15 at 7:46 AM
William Blair Weighs in on Taysha Gene Therapies, Inc.s Q1 2021 Earnings (NASDAQ:TSHA)William Blair Weighs in on Taysha Gene Therapies, Inc.'s Q1 2021 Earnings (NASDAQ:TSHA)
americanbankingnews.com - April 15 at 6:18 AM
BRIEF-Taysha Gene Therapies Announces New Data On Multiple Preclinical Programs And Upcoming Research And Development DayBRIEF-Taysha Gene Therapies Announces New Data On Multiple Preclinical Programs And Upcoming Research And Development Day
msn.com - April 14 at 10:48 AM
Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 4.8% After Analyst UpgradeTaysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 4.8% After Analyst Upgrade
americanbankingnews.com - April 13 at 11:58 AM
Taysha Gene Therapies (NASDAQ:TSHA) PT Raised to $43.00 at Morgan StanleyTaysha Gene Therapies (NASDAQ:TSHA) PT Raised to $43.00 at Morgan Stanley
americanbankingnews.com - April 13 at 11:20 AM
Dallas’ Taysha Gene Therapies Gets Worldwide Rights to Gene Therapy That Treats a Rare Neurodegenerative DiseaseDallas’ Taysha Gene Therapies Gets Worldwide Rights to Gene Therapy That Treats a Rare Neurodegenerative Disease
dallasinnovates.com - April 12 at 11:38 PM
Taysha Gene Therapies Stock Is Trading Higher After Buying Rights To New Gene Therapy Candidate For Neurodegenerative DiseaseTaysha Gene Therapies Stock Is Trading Higher After Buying Rights To New Gene Therapy Candidate For Neurodegenerative Disease
finance.yahoo.com - April 12 at 6:38 PM
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $67.50 at Chardan CapitalTaysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $67.50 at Chardan Capital
americanbankingnews.com - April 12 at 5:00 PM
Why Taysha Gene Therapiess Stock is Trading Higher TodayWhy Taysha Gene Therapies's Stock is Trading Higher Today
msn.com - April 12 at 1:37 PM
Taysha Gene Therapies Acquires Exclusive Worldwide…Taysha Gene Therapies Acquires Exclusive Worldwide…
pharmiweb.com - April 12 at 1:37 PM
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $21.19Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $21.19
americanbankingnews.com - April 12 at 11:12 AM
Taysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program, Now Known as TSHA-120, for the Treatment of GiaTaysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program, Now Known as TSHA-120, for the Treatment of Gia
us.acrofan.com - April 12 at 8:36 AM
BRIEF-Taysha Gene Therapies Acquires Exclusive Worldwide Rights To Clinical-Stage Aav9 Gene Therapy Program, Now Known As Tsha-120, For Giant Axonal NeuropathyBRIEF-Taysha Gene Therapies Acquires Exclusive Worldwide Rights To Clinical-Stage Aav9 Gene Therapy Program, Now Known As Tsha-120, For Giant Axonal Neuropathy
msn.com - April 12 at 8:36 AM
Taysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program, Now Known as TSHA-120, for the Treatment of Giant Axonal Neuropathy, a Rare and Severe Neurodegenerative DiseaseTaysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program, Now Known as TSHA-120, for the Treatment of Giant Axonal Neuropathy, a Rare and Severe Neurodegenerative Disease
finance.yahoo.com - April 12 at 8:36 AM
Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare ConferencesTaysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences
finance.yahoo.com - April 5 at 7:42 AM
Financial Review: Surface Oncology (NASDAQ:SURF) versus Taysha Gene Therapies (NASDAQ:TSHA)Financial Review: Surface Oncology (NASDAQ:SURF) versus Taysha Gene Therapies (NASDAQ:TSHA)
americanbankingnews.com - March 30 at 6:36 PM
 Brokerages Expect Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Will Post Earnings of -$0.45 Per Share Brokerages Expect Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Will Post Earnings of -$0.45 Per Share
americanbankingnews.com - March 30 at 4:56 AM
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $21.54Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $21.54
americanbankingnews.com - March 29 at 1:46 PM
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by BrokeragesTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Brokerages
americanbankingnews.com - March 29 at 9:02 AM
Heres Why Were Not Too Worried About Taysha Gene Therapies (NASDAQ:TSHA) Cash Burn SituationHere's Why We're Not Too Worried About Taysha Gene Therapies' (NASDAQ:TSHA) Cash Burn Situation
finance.yahoo.com - March 24 at 3:08 PM
DateCompanyBrokerageAction
4/19/2021Rubius TherapeuticsMorgan StanleyBoost Price Target
3/22/2021Rubius TherapeuticsHC WainwrightBoost Price Target
3/22/2021Rubius TherapeuticsSVB LeerinkBoost Price Target
10/14/2020Rubius TherapeuticsJPMorgan Chase & Co.Initiated Coverage
3/13/2020Rubius TherapeuticsGuggenheimLower Price Target
9/9/2019Rubius TherapeuticsRobert W. BairdInitiated Coverage
2/3/2021InhibrxCredit Suisse GroupBoost Price Target
10/15/2020InhibrxLifesci CapitalReiterated Rating
9/14/2020InhibrxJefferies Financial GroupInitiated Coverage
9/14/2020InhibrxEvercore ISIInitiated Coverage
4/13/2021MesoblastMaxim GroupUpgrade
12/4/2020MesoblastChardan CapitalDowngrade
10/22/2020MesoblastRoyal Bank of CanadaInitiated Coverage
5/28/2020MesoblastLADENBURG THALM/SH SHBoost Price Target
12/19/2019MesoblastDawson JamesInitiated Coverage
10/22/2019MesoblastCantor FitzgeraldReiterated Rating
9/10/2019MesoblastOppenheimerSet Price Target
12/15/2020Adverum BiotechnologiesUBS GroupInitiated Coverage
11/12/2020Adverum BiotechnologiesRaymond JamesUpgrade
8/10/2020Adverum BiotechnologiesPiper SandlerBoost Price Target
5/5/2020Adverum BiotechnologiesSunTrust BanksUpgrade
4/28/2020Adverum BiotechnologiesThe Goldman Sachs GroupInitiated Coverage
1/13/2020Adverum BiotechnologiesPiper Jaffray CompaniesBoost Price Target
3/1/2021Taysha Gene TherapiesWilliam BlairInitiated Coverage
(Data available from 4/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.